chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a health care worker refers to a patient of 64 year old. The patients medical history and current conditions are not reported. It was reported that the patient received two doses of ZOSTAVAX of 0.5ml (lot # J011338 and expiry date 19-DEC-2014), the first dose on 08-12/2013 and the second dose on 09/25/2014. No adverse effect was reported. The patient did not seek any medical attention. Product quality complaint was not reported. The outcome of the event is unknown.  Additional information has been requested.
Her arm was a little sore after the first dose.; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Her arm was a little sore after the first dose.) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy to nuts, Drug allergy, Blood pressure high (Increased medication last couple of years.), High cholesterol (Started medication 6 months ago.) and CPAP (Improving, Very mild). Concomitant products included VALSARTAN and DILTIAZEM for Blood pressure high, ATORVASTATIN for High cholesterol, ESTRADIOL (ESTROGEN), PROGESTERONE, TESTOSTERONE and FLUOXETINE for Menopause.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2021, the patient experienced VACCINATION SITE PAIN (Her arm was a little sore after the first dose.). At the time of the report, VACCINATION SITE PAIN (Her arm was a little sore after the first dose.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment information was provided.   This case was linked to MOD-2021-026766 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-Jul-2021: Follow up received and New events added.
Headache, Diarrhea, Low grade fever, body aches, fatigue Narrative:  Developed a low grade fever, fatigue, body aches, headache, lightheadedness, and diarrhea following vaccine administration. Resolved by 12/30/20.
The COVID 19 vaccine expired on 8/31/22; however, the expired COVID 19 vaccine was administered to the patient on 9/1/22. No adverse reaction reported by parent.
Patient developed febrile illness the next day following the day of receiving dose#2 of the vaccine. On the following day, he developed chest pain and shortness of breath so he was transferred to emergency room and admitted. He was diagnosed with mycarditis based in clinical symptoms and very elevated troponin
having a stroke; I began to experience numbness on my entire left side, left arm; hand weakness, left leg weakness; trouble walking/stumbling; speech problems; slurred speech; fatigue; injection site pain; nausea; pain in my left hip; This is a spontaneous report from a contactable consumer (patient). A 61-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: ER8727), via an unspecified route of administration, administered in left arm on 29Mar2021 16:30 at single dose for COVID-19 immunisation. The patient's medical history included chronic fatigue syndrome, fibromyalgia, sulfa allergy. The patient was not pregnant at the time of vaccination. The patient's concomitant medications were not reported. Facility where the most recent COVID-19 vaccine was administered was Pharmacy/drug store. The patient did not receive any other vaccines within 4 weeks prior to COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination and has not been tested for COVID-19 since the vaccination. The patient experienced immediate fatigue, injection site pain, nausea, along with pain in her left hip the day after her first Covid vaccine on 30Mar2021 05:00 (Tuesday). The injection site pain resolved after a few days, but she continued to be exhausted and nauseous all week. On 02Apr2021 (Friday), she began to experience numbness on my entire left side, left arm and hand weakness, left leg weakness, trouble walking, speech problems, having to really think about her words (her daughter-in-law was typing this as she could not), slurred speech, stumbling. Her family was concerned she was having a stroke on 02Apr2021 05:00, but have no drooping in her face. She was so scared that she will not be getting her second vaccine. She have not gone to a doctor, as she do not have insurance. The symptoms were continuing. No treatment was received for the adverse events. The outcome of the event 'injection site pain' was recovered; the events fatigue and nausea was not recovered; and unknown for the rest of the events. Events were reported as non-serious.  Information on lot/batch number was available. Additional information has been requested.
Noticed two reactions; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of VACCINATION COMPLICATION (Noticed two reactions) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History Information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Noticed two reactions). At the time of the report, VACCINATION COMPLICATION (Noticed two reactions) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant Concomitant medications were reported.   No Treatment information for the event was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 02-Feb-2021 and was forwarded to Moderna on 04-Feb-2021.    Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of VACCINATION COMPLICATION (Noticed two reactions) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History Information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Noticed two reactions). At the time of the report, VACCINATION COMPLICATION (Noticed two reactions) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant Concomitant medications were reported.   No Treatment information for the event was provided.
Pt encountered a migraine that continued intensifying several days after vaccination, was seen by an ED/outpatient service. Had described having previous diagnosis of Hashimoto's and was not supposed to receive vaccination due to lowered immune system.
Swelling at the injection site; Pain at the injection site; burning upon administration; Redness at the injection site; Warmth at the injection site; This is a spontaneous report from a contactable healthcare professional (patient). A 31-year-old female patient (non-pregnant) received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number: EJ1284), via an unspecified route of administration in left arm, on 04Jan2021 at 12:00, at a single dose, COVID-19 immunization. The patient's medical history included polycystic ovarian syndrome (PCOS) and fish allergy. The patient's concomitant medications included Curcuma longa (TURMERIC), probiotics, and unspecified multivitamin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The most recent COVID-19 vaccine was administered in a hospital. On 04Jan2021 at 12:00 PM, the patient experienced swelling, pain, redness, and warmth at the injection site lasting for 3 days. It was burning upon administration. The events were considered non-serious. No treatment was received for the adverse events. Since the vaccination, the patient has not been tested for COVID-19. The patient recovered from the events on 07Jan2021.  No follow-up attempts are possible. No further information is expected.
6 months after the vaccine was given, patient still has a "lipoma".  Said to be a raised hard protruding 1.5 inches on right deltoid.  Patient saw general surgeon and was told they wouldn't remove or do an incision to drain.
Lightheadness, tachycardia (110s), cold clammy hands, hypertensive (149/95), set in within 5-10 minutes of vaccine. Chills 10 minutes later. Treated with Benadryl, water and snack. Remained at clinic x2 hours until symptoms resolved.  Premedicated prior to vaccine with ibuprofen at 7:25am 400mg to avoid chills etc anticipated with the second dose.
initially sore at the injection site; redness at injection site was immediate and continued for ~14 days post-injection; sore elbow started 3 days post injection and has continued for 2.5 weeks. Initially was really painful when arm was moved, pain has decreased to a small ache, but painful to lift heavy items. Ibuproven has controlled the pain
PATIENT RECIEVED VARIVAX VACCINE ON 12-17-04 RETURNED TO OFFICE ON 12-21-04 WITH SCATTERED BLISTERS. THAN BEGAN TO APPEAR ON 12-20-04.
Shot at 10am -2pm Headache starts, located in the forehead/eye area. -3-4pm Tiredness/Fatigue sets in. -7-8pm Chills and slight fever start. Next day Still tired and fatigued, again chills/fever start during the day but tylenol helps.   -Dizziness starts along with tinnitus around 2pm. Lasts 4-5 hours.  -Tired and fatigued the rest of the day.
After receiving the Varicella vaccination (1st time) Pox-like raised bumps on face, torso and legs appeared 2 days later.
Deep vein thrombosis; Pulmonary embolism; This case was received via VAERS (Reference number: 1358680) on 15-Jun-2021 and was forwarded to Moderna on 15-Jun-2021.    This regulatory authority case was reported by an other health care professional and describes the occurrence of DEEP VEIN THROMBOSIS (Deep vein thrombosis) and PULMONARY EMBOLISM (Pulmonary embolism) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Parkinson's disease and Latex allergy. Concomitant products included CARBIDOPA, LEVODOPA (CARBIDOPA LEVODOPA), TAMSULOSIN, DROXIDOPA (NORTHERA), MELATONIN, CYANOCOBALAMIN (B-12), FINASTERIDE, POTASSIUM, CITALOPRAM and ROSUVASTATIN for an unknown indication.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DEEP VEIN THROMBOSIS (Deep vein thrombosis) (seriousness criterion medically significant) and PULMONARY EMBOLISM (Pulmonary embolism) (seriousness criterion medically significant). At the time of the report, DEEP VEIN THROMBOSIS (Deep vein thrombosis) and PULMONARY EMBOLISM (Pulmonary embolism) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medication information was not provided.  Very limited information regarding the events has been provided at this time. Further information is not expected.; Sender's Comments: Very limited information regarding the events has been provided at this time. Further information is not expected.
broke out in a rash all over her body; hives; she is still itching; This is a spontaneous report from a contactable consumer (patient). A 67-years-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for injection, Lot number: ELK3302, Expiration Date: not reported) via an unspecified route of administration in left arm on 28Jan2021as a single dose for COVID-19 immunization. Patient historical vaccine included 1st dose of BNT162B2. Patient had not received other vaccines on the same day as the COVID vaccine. Medical history included high blood pressure. Concomitant medication(s) included metoprolol. The patient experienced, broke out in a rash all over her body was reported as worsened, hive and she is still itching on 28Jan2021. The clinical outcome for the events was not recovered.  Additional Context: the patient stated that she had her second COVID shot and broke out in a rash all over her body and also stated that it started on Thursday and she was still itching. The patient mentioned that she went to her doctor, and the doctor thought that maybe the patients hands were just from dishwashing but the patient stated that it was her whole body. The patient stated that she asked the doctor for a Benadryl shot, but the doctor told her she can't take Benadryl with the shot, and was asking whether it was true. The patient did not know how to get rid of the hives. The patient stated that the first dose was okay, but this one was hell. The outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Patient is a 80 y.o. male patient of MD with a history of remote tobacco abuse who was admitted 12/28/2022 for COVID infection with superimposed multifocal pneumonia. Started on empiric antibiotics as well as Remdesivir and Decadron. He was given Tocilizumab 12/31/2022. Patient was initially on BiPAP but ultimately required intubation due to hypoxia and increased work of breath 1/01/23. Patient was also started on DEXA ARDS protocol 1/01/2023. On 1/03/23 nephrology was consulted due to acute renal failure. Patient was started on CRRT. Given increasing pressor requirements and renal failure, palliative care was consulted 1/05 to discuss goals of care. Patient's code status was changed to DNR-CCA. On the night of 1/05 CXR showed a 2.1 cm right apical pneumothorax. Chest tube was urgently placed. Unfortunately, blood pressure continued to decline despite maximum pressor support with 100 of Levophed, Vaso, and Neo-synephrine. Time of death was called 0021 on 1/06/2023.    Discharge Diagnoses: Acute Hypoxemic Respiratory Failure Pulmonary Infiltrates COVID Infection Acute metabolic encephalopathy  Septic Shock Emphysema History of Tobacco Abuse Elevated Troponin  Acute Kidney Injury
fever for almost 8 days; This case was reported by a consumer and described the occurrence of fever in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 1 day after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was recovered/resolved.   It was unknown if the reporter considered the fever to be related to Shingrix.  AAdditional details were provided as follows: The age at vaccination was not reported. The patient had fever for almost 8 days starting the day after the first Shingrix vaccine. The patient stated that was unusual. The patient wanted to know if he did not take the second dose and still he would protected and approximately how much. The patient was wondering whom to talk on your medical team to get some more information to make a more informed decision.
Minutes after injection, I developed pressure and pain in my ears followed by ringing. I was observed for 30 minutes due to my prior anaphylactic reaction to a wasp sting. 40 minutes after injection, 10 minutes after leaving the pharmacy, I developed a welt-sized hive on my left foot. It was gone by the time I returned home. I then had hives on my left forearm. They went away with out treatment. At thas point, I had itching and swelling of the thumb on my left hand. That was somewhat painful. That was also the location of my wasp sting in July 2020. That also disappeared without any treatment from my of oinment or benadryl. I then found hives on my waist and stomach while lastly experiencing swelling on my lip. Again, this was all methodical almost over the course of 5-6 hours after injection. One hive would go away to have hives appear in another location. At 9pm that evening, I experienced sudden lower back pain on the right side and had difficulty walking due to the pain resulting from weight being placed on that side. My research suggested it was sciatica. I have no history of sciatica other than some discomfort during my pregnancies, the last of which was nine years ago. I treated this with 8oomg of ibuprofen and went to bed. Several hours later, I was awoken by the right leg shaking in my sleep. It was like a significant tremor. It stopped within a few minutes of me waking up. I was able to go back to sleep. However, I continued to experience sciatic pain on Sunday, March 28th and a bit today, March 29th. It has dissipated significantly and I am not functional. There was no repetition of the leg tremor after the initial and sole incident. I continued to have sporadic hives on my upper body on Sunday, March 28th. There are none present today, March 29th.
The the day after receiving the vaccine my arm was sore in the upper arm. On the night of the 12th I noticed a rash. It was smaller then hives, 3inches above my elbow to my shoulder. It is itching and now my whole arm hurt. I put some Cortizone 10 on it last night but it did not help. It kept me up most of last night. I called my doctor this morning, and I spoke with Dr. nurse who told me to put cold compresses on it.
Admitted with chest pain and shortness of breath developing the morning of admission (15 days following COVID and influenza vaccination); diagnosed with pericarditis. Patient with chest pain, elevated inflammatory markers, abnormal EKG, troponin negative x3, TTE without pericardial effusion, mild LVH, patient's symptoms rapidly improved with treatment of ibuprofen and colchicine,
other zoster-related conditions; shingles; Information has been received from a lawyer regarding a case in litigation concerning a patient (pt) of unknown age and gender. The pt's medical history, concurrent conditions and concomitant medications were not provided. On or about 20-SEP-2012, the pt was vaccinated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, anatomical location, lot#, expiration date were unknown) by a healthcare professional for the long-term prevention of shingles and zoster-related conditions. Subsequent to pt's zoster vaccine live (ZOSTAVAX) inoculation, pt was treated by a healthcare professional for shingles and other zoster-related conditions. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and would continue to suffer such losses, and damages in the future. The outcome of shingles and zoster-related conditions was unknown and the causal relationship between shingles, zoster-related conditions and zoster vaccine live (ZOSTAVAX) was considered related.
No adverse event; The patient was vaccinated after BUD; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (The patient was vaccinated after BUD) and NO ADVERSE EVENT (No adverse event) in a 71-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 084J21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 26-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 26-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (The patient was vaccinated after BUD). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (The patient was vaccinated after BUD) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (The patient was vaccinated after BUD).    The patient registry ID was reported as Unknown.  Concomitant medication of the patient was not reported.  No treatment information was provided by the reporter.
This is a spontaneous report from a contactable Nurse. This Nurse reported for a 67-year-old female consumer that: A 67-year-old female non-pregnant patient received bnt162b2 (COMIRNATY), administered in unknown (Lot number: unknown at the age of 67 years as dose 3, Intramuscular, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medications were not reported. The following information was reported: Patient received booster dose of Pfizer VXN, remained in observation for 20 minutes without symptoms. On drive home, she "didn't feel quite right", then developed neck and chest pain. Patient takes nitro-glycerine for underlying cardiac disorder, so took nitro and pain stopped onset on 10Nov2021 without come of recovered. Therapeutic measures were nitro-glycerine taken as a result of Recovered Vaccination history included: Comirnaty (product=COVID 19, lot number=EX. unknown, number=1, vaccine location=left arm), COVID 19, lot number=unknown, number=2, vaccine location=left arm) for Covid-19 immunisation. Additional information: The patient had not received any other vaccine within 4 weeks. The patient had not been diagnosed with COVID-19 prior to vaccination and had not been tested since the vaccination. Patient was not hospitalized, case was assessed as non-serious, No treatment was taken. The lot number for the vaccine [BNT162B2] was not provided and will be requested during follow up.
had better breathing and perfect oxygen level after receiving the Moderna COVID-19 vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (had better breathing and perfect oxygen level after receiving the Moderna COVID-19 vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (had better breathing and perfect oxygen level after receiving the Moderna COVID-19 vaccine). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (had better breathing and perfect oxygen level after receiving the Moderna COVID-19 vaccine) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was provided Treatment medication was not provided